# Haichuang Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haichuang-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.hinovapharma.com
- Total disclosed funding: $187M
- Latest round: Series C (Sep 30, 2020)
- Investors on record: 16

## About

Established in 2013 and based in Chengdu, China, Haichuang Pharmaceutical Co., Ltd. is a drug discovery and development company that focuses on therapeutic areas.

The company has 10 products under development. In its current product pipeline, HC-1119 is in two Phase III clinical trials for the treatment of desmoid-resistant prostate cancer; HP501 for the treatment of hyperuricemia and gout has completed a Phase II clinical trial; HP558, a potential therapeutic agent for gastrointestinal tumors, has completed a Phase I clinical trial in Europe and a Phase II clinical trial application has been approved by the NMPA; and HP518, an oral PROTAC agent for AR, is in Phase I clinical trial in Australia. The company has four technology platforms including PROTAC targeted protein degradation technology platform, deuterated drug research and development platform, targeted drug discovery and verification platform, and lead compound optimization and screening platform.

## Funding rounds

- Series C, Sep 30, 2020, $147M — Infinity Group, Founder H Fund, Hongtai Aplus, DNV Capital, Shenzhen Investment Holdings, Sealand Innovation, Rongkaide Fund, FTU Fund, CCB International, Qindao Capital, Tigermed, Sinopharm-CICC Capital
- Series B, Jul 26, 2019, $40M — Hermed Capital, Langsheng Investment, Shanghai Fosun Pharmaceutical (Group), WaterWoods Capital

## Investors

- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series B
- Langsheng Investment (https://capitalatlas.ai/funds/langsheng-investment) — Series B
- Shanghai Fosun Pharmaceutical (Group) — Series B
- WaterWoods Capital (https://capitalatlas.ai/funds/waterwoods-capital) — Series B
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series C
- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Series C
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series C
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series C
- Shenzhen Investment Holdings — Series C
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series C
- Rongkaide Fund (https://capitalatlas.ai/funds/rongkaide-fund) — Series C
- FTU Fund (https://capitalatlas.ai/funds/ftu-fund) — Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- Qindao Capital — Series C
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series C
- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series C